Traws Pharma (TRAW) plans to develop potential therapies for the treatment and prevention of hantavirus infections using its existing portfolio of antiviral drug candidates targeting negative-strand RNA viruses, the company said Friday.

The company said the candidates have demonstrated activity against negative-strand virus replication and could be developed as standalone or combination therapies.

Traws also plans to leverage its existing development infrastructure and proprietary chemical libraries to identify optimal Hantaan virus treatments.

There are currently no approved treatments for Hantaan pulmonary disease, a rodent-borne infection with human fatality rates ranging from 30% to 50%, the company said.

Traws Pharma shares were up 33% in recent premarket activity on Friday.